| 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 司的关联关系 | 上市公司 核算的会计科目 | 2025 年期 初占用资 金余额 | 2025 年半年度 占用累计发生 金额 | 2025 年半 年度占用 资金的利 | 2025 年半 年度偿还 累计发生 | 2025 年半 年度末占用 资金余额 | 占用形成 原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | （不含利息） | 息 （如有） | 金额 | | | | | 控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际 | | | | | | | | | | | | 控制人及其附属企 | | | | | | | | | | | | 业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 其他关联方及其附 | | | ...

特一药业集团股份有限公司 TEYI PHARMACEUTICAL GROUP CO.,LTD （注册地址：台山市台城长兴路9、11号） 2025 年半年度财务报告 2025 年 8 月 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 286,258,083.96 | 457,414,315.11 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 75,000,000.00 | | | 衍生金融资产 | | | | 应收票据 | 71,589,420.53 | 106,575,601.48 | | 应收账款 | 67,970,396.27 | 98,746,349.39 | | 应收款项融资 | | | | 预付款项 | 19,695,486.14 | 10,403,104.32 | | 应收保费 | | | | 应收分保账款 | | | | 应收分保合同准备金 | | | | 其他应收款 | 1,211,196.25 | 9,375,183.00 | | 其中：应收利息 | | 458,2 ...

证券代码：002728 证券简称：特一药业 公告编号：2025-058 特一药业集团股份有限公司 关于 2025 年半年度募集资金存放、管理与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 根据中国证券监督管理委员会《上市公司募集资金监管规则》《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作》以及《深圳证券交易所上市公司自律监管指南第 2 号 ——公告格式》的相关规定，特一药业集团股份有限公司（以下简称"公司"）董事会编制了截至 2025 年 6 月 30 日募集资金存放、管理与使用情况的专项报告。 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额和资金到位时间 1、2017 年公开发行可转换公司债券募集资金 经中国证券监督管理委员会证监许可[2017]2004 号文《关于核准特一药业集团股份有限公司公 开发行可转换公司债券的批复》核准，本公司向社会公开发行面值总额 3.54 亿元的可转换公司债券， 每张面值 100 元，共计 354 万张，期限 6 年。公司本次发行可转债募集资金总额为人民币 354, ...

证券代码：002728 证券简称：特一药业 公告编号：2025-056 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）第六届董事会第 三次会议于 2025 年 8 月 21 日 10:00 在公司子公司海南海力制药有限公司会议室采用现 场及电子通信方式召开，会议通知于 2025 年 8 月 19 日以电子邮件方式发出，会议应出 席董事 6 名，实际出席 6 名。公司非董事高级管理人员列席了本次会议。会议的召集、 召开符合《公司法》和《公司章程》的相关规定。 二、董事会会议审议情况 会议由董事长许荣煌主持，全体董事经过审议，以现场和电子通信方式进行表决， 通过了如下决议： 1、审议通过《关于审议公司 2025 年半年度报告的议案》 公司 2025 年 1-6 月的经营情况及财务状况已经公司相关部门编制完成，具体内容 详见《2025 年半年度报告》，该报告拟于 2025 年 8 月 22 日对外报出。 公司 2025 年半年度财务信息已由公司审计委员会审议并取得了全体委员明确同意 的意见。 特一药业集团股份有限公司 关于第六届董事会第三次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准 ...

特一药业集团股份有限公司 TEYI PHARMACEUTICAL GROUP CO.,LTD （注册地址：台山市台城长兴路9、11号） 2025 年半年度报告 2025 年 8 月 特一药业集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人许荣煌、主管会计工作负责人陈习良及会计机构负责人(会计 主管人员)蔡壁坚声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 公司在本报告"第三节-管理层讨论与分析"中"十、公司面临的风险和 应对措施"中详细描述了公司未来经营中可能存在的风险及应对措施，敬请 投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | | 1 | | --- | --- | --- | --- | | 第二节 | 公 ...

Group 1 - The stock price of Te Yi Pharmaceutical reached 9.28 yuan as of the close on August 15, 2025, with an increase of 0.10 yuan, representing a rise of 1.09% [1] - The trading volume on that day was 153,060 hands, with a transaction amount of 1.41 billion yuan [1] - Te Yi Pharmaceutical operates in the pharmaceutical manufacturing industry, primarily engaged in the research, production, and sales of traditional Chinese medicine, chemical preparations, chemical raw materials, and chemical products [1] Group 2 - In the revenue composition for 2024, the pharmaceutical industry accounted for 97.65% of the company's total revenue [1] - On the evening of August 15, Te Yi Pharmaceutical announced that its sixth board of directors' second meeting approved a proposal to use part of the idle raised funds from the 2023 fiscal year for cash management and to temporarily supplement working capital [1]

Group 1 - The company held its sixth board meeting on August 15, 2025, where all six attending directors approved the resolutions [2][3][4] - The board approved the use of idle funds from a specific stock issuance to temporarily supplement working capital and for cash management [3][4][17] Group 2 - The company raised a total of approximately 275 million yuan from the issuance of 20,146,514 shares at a price of 13.65 yuan per share, with a net amount of about 268.89 million yuan after deducting issuance costs [7][18] - As of June 30, 2025, the company had utilized 60 million yuan of the raised funds, leaving a balance of approximately 21.05 million yuan [8][20] - The company plans to use up to 100 million yuan, which is 37.19% of the net raised funds, to temporarily supplement working capital for a period not exceeding 12 months [11][12] Group 3 - The company intends to use up to 90 million yuan of idle funds for cash management, focusing on safe and liquid investment products [17][22] - The cash management will not affect the normal operation of the fundraising projects and is expected to enhance the efficiency of fund usage [30][31]

东莞证券股份有限公司（以下简称"东莞证券"或"保荐机构"）作为特一药业集 团股份有限公司（以下简称"特一药业"或"公司"）2023年度以简易程序向特定对象 发行股票的保荐机构，根据《上市公司募集资金监管规则》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》等 法律法规的有关规定，对特一药业拟使用2023年度以简易程序向特定对象发行股票部分 闲置募集资金进行现金管理的情况进行了审慎核查，并出具本核查意见。核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意特一药业集团股份有限公司向特定对象发行 股票注册的批复》（证监许可【2023】1987号）同意注册，公司向9家特定投资者发行 人民币普通股20,146,514股，发行价格为每股13.65元。截至2023年9月14日，本公司实 际以简易程序向特定对象发行人民币普通股（A股）20,146,514股，募集资金总额 股份有限公司于2023年9月14日汇入本公司募集资金专项存储账户内。另扣审计费、律 师费、发行手续费等发行费用874,949.91元（不含税金额825,639.53元），实际募集资 金 ...

Core Viewpoint - Dongguan Securities has conducted a thorough review of the temporary use of idle funds raised by Te Yi Pharmaceutical Group Co., Ltd. through a simplified procedure for issuing shares to specific targets in 2023, confirming compliance with relevant regulations and the necessity of the fund usage [1][7][8] Fundraising Basic Situation - Te Yi Pharmaceutical received approval from the China Securities Regulatory Commission on September 4, 2023, to issue shares, raising a net amount of approximately RMB 268.89 million after deducting issuance costs [1] - The funds have been fully received and verified by Da Xin Accounting Firm on September 15, 2023 [1] Fund Usage and Idle Reasons - As of June 30, 2025, the company has utilized RMB 60 million of the raised funds, leaving a balance of RMB 210.48 million, which includes net interest income [2] - The idle funds are primarily due to the construction cycle required for the modernization of traditional Chinese medicine product lines and technology upgrades [3] Previous Use of Idle Funds - On December 26, 2024, the company’s board approved the temporary use of up to RMB 200 million of idle funds for working capital, which has since been fully returned to the dedicated fundraising account by July 2, 2025 [4][5] Current Proposal for Idle Funds - The company plans to temporarily use up to RMB 100 million (37.19% of the net amount raised) of idle funds for working capital, with a repayment period not exceeding 12 months [5][7] - This usage aims to enhance fund efficiency, reduce financial costs, and maintain the interests of the company and its shareholders [6][8] Review and Approval Process - The board has approved the plan to use idle funds, ensuring compliance with relevant regulations and confirming that it will not affect the implementation of original fundraising projects [7][8]

Group 1 - The company announced the approval of two proposals by its sixth board of directors' second meeting, which include the temporary use of idle raised funds for supplementing working capital and cash management [2] - The proposals involve utilizing part of the funds raised through a simplified procedure for specific targets in the year 2023 [2] - The announcements indicate the company's strategic approach to managing its financial resources effectively [2]